XENE – xenon pharmaceuticals inc. - common shares (US:NASDAQ)

News

Xenon to Report Q3 2024 Financial Results on November 12, 2024 [Canadian Business Journal (Canada)]
Xenon to Report Q3 2024 Financial Results on November 12, 2024
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $53.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com